IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v31y2013i9p823-839.html
   My bibliography  Save this article

Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States

Author

Listed:
  • Reginald Villacorta
  • Joel Hay
  • Andrew Messali

Abstract

Under typical US willingness-to-pay cutoffs, ustekinumab 90 mg is not cost effective compared with etanercept 50 mg therapy in moderate to severe psoriasis patients for the base-case 3-year time horizon. Ustekinumab 45 mg dominates etanercept 50 mg therapy for an equivalent patient psoriasis severity and time horizon. Copyright Springer International Publishing Switzerland 2013

Suggested Citation

  • Reginald Villacorta & Joel Hay & Andrew Messali, 2013. "Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States," PharmacoEconomics, Springer, vol. 31(9), pages 823-839, September.
  • Handle: RePEc:spr:pharme:v:31:y:2013:i:9:p:823-839
    DOI: 10.1007/s40273-013-0078-x
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40273-013-0078-x
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s40273-013-0078-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Brazier, John & Ratcliffe, Julie & Salomon, Joshua & Tsuchiya, Aki, 2016. "Measuring and Valuing Health Benefits for Economic Evaluation," OUP Catalogue, Oxford University Press, edition 2, number 9780198725923.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Christian Kromer & Daniel Celis & Diana Sonntag & Wiebke K Peitsch, 2018. "Biologicals and small molecules in psoriasis: A systematic review of economic evaluations," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-22, January.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joanna Coast & Hareth Al‐Janabi & Eileen J. Sutton & Susan A. Horrocks & A. Jane Vosper & Dawn R. Swancutt & Terry N. Flynn, 2012. "Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 730-741, June.
    2. Joanna M Charles & Deirdre M Harrington & Melanie J Davies & Charlotte L Edwardson & Trish Gorely & Danielle H Bodicoat & Kamlesh Khunti & Lauren B Sherar & Thomas Yates & Rhiannon Tudor Edwards, 2019. "Micro-costing and a cost-consequence analysis of the ‘Girls Active’ programme: A cluster randomised controlled trial," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-17, August.
    3. Ratcliffe, Julie & Huynh, Elisabeth & Chen, Gang & Stevens, Katherine & Swait, Joffre & Brazier, John & Sawyer, Michael & Roberts, Rachel & Flynn, Terry, 2016. "Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm," Social Science & Medicine, Elsevier, vol. 157(C), pages 48-59.
    4. Richard Norman & Brendan Mulhern & Emily Lancsar & Paula Lorgelly & Julie Ratcliffe & Deborah Street & Rosalie Viney, 2023. "The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia," PharmacoEconomics, Springer, vol. 41(4), pages 427-438, April.
    5. Makai, Peter & Brouwer, Werner B.F. & Koopmanschap, Marc A. & Stolk, Elly A. & Nieboer, Anna P., 2014. "Quality of life instruments for economic evaluations in health and social care for older people: A systematic review," Social Science & Medicine, Elsevier, vol. 102(C), pages 83-93.
    6. Stevens, K, 2010. "Valuation of the Child Health Utility Index 9D (CHU9D)," MPRA Paper 29938, University Library of Munich, Germany.
    7. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    8. Ian M. McCarthy, 2015. "Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1588-1603, December.
    9. Zhongliang Zhou & Yu Fang & Zhiying Zhou & Dan Li & Dan Wang & Yanli Li & Li Lu & Jianmin Gao & Gang Chen, 2017. "Assessing Income-Related Health Inequality and Horizontal Inequity in China," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 132(1), pages 241-256, May.
    10. Eliza Lai Yi Wong & Richard Huan Xu & Annie Wai Ling Cheung, 2020. "Health-related quality of life in elderly people with hypertension and the estimation of minimally important difference using EQ-5D-5L in Hong Kong SAR, China," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 869-879, August.
    11. David J. Mott & Nancy J. Devlin & Simone Kreimeier & Richard Norman & Koonal K. Shah & Oliver Rivero-Arias, 2022. "Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 129-137, December.
    12. Billingsley Kaambwa & Gang Chen & Julie Ratcliffe & Angelo Iezzi & Aimee Maxwell & Jeff Richardson, 2017. "Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs)," PharmacoEconomics, Springer, vol. 35(1), pages 111-124, January.
    13. Donna Rowen & John Brazier & Anju Keetharuth & Aki Tsuchiya & Clara Mukuria, 2016. "Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 89-104, February.
    14. Louis S. Matza & Katherine J. Kim & Holly Yu & Katherine A. Belden & Antonia F. Chen & Mark Kurd & Bruce Y. Lee & Jason Webb, 2019. "Health state utilities associated with post-surgical Staphylococcus aureus infections," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 819-827, August.
    15. Donna Rowen & John Brazier & Clara Mukuria & Anju Keetharuth & Arne Risa Hole & Aki Tsuchiya & Sophie Whyte & Phil Shackley, 2016. "Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life," Medical Decision Making, , vol. 36(2), pages 210-222, February.
    16. Hausman, Daniel M., 2023. "Eliciting preferences and respecting values: Why ask?," Social Science & Medicine, Elsevier, vol. 320(C).
    17. Richard Cookson & Owen Cotton-Barrett & Matthew Adler & Miqdad Asaria & Toby Ord, 2016. "Years of good life based on income and health: Re-engineering cost-benefit analysis to examine policy impacts on wellbeing and distributive justice," Working Papers 132cherp, Centre for Health Economics, University of York.
    18. Tara Lavelle & Eve Wittenberg & Kara Lamarand & Lisa Prosser, 2014. "Variation in the Spillover Effects of Illness on Parents, Spouses, and Children of the Chronically Ill," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 117-124, April.
    19. Thébaut, Clémence, 2013. "Dealing with moral dilemma raised by adaptive preferences in health technology assessment: The example of growth hormones and bilateral cochlear implants," Social Science & Medicine, Elsevier, vol. 99(C), pages 102-109.
    20. Renske J. Hoefman & Job Exel & Werner B. F. Brouwer, 2017. "Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US," PharmacoEconomics, Springer, vol. 35(4), pages 469-478, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:31:y:2013:i:9:p:823-839. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.